203 related articles for article (PubMed ID: 15385083)
21. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258
[TBL] [Abstract][Full Text] [Related]
22. Assessment of temperature-induced hERG channel blockade variation by drugs.
Kauthale RR; Dadarkar SS; Husain R; Karande VV; Gatne MM
J Appl Toxicol; 2015 Jul; 35(7):799-805. PubMed ID: 25348819
[TBL] [Abstract][Full Text] [Related]
23. Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells.
Du X; Lu D; Daharsh ED; Yao A; Dewoody R; Yao JA
J Pharmacol Toxicol Methods; 2006; 54(2):164-72. PubMed ID: 16782359
[TBL] [Abstract][Full Text] [Related]
24. Blockade of HERG and Kv1.5 by ketoconazole.
Dumaine R; Roy ML; Brown AM
J Pharmacol Exp Ther; 1998 Aug; 286(2):727-35. PubMed ID: 9694927
[TBL] [Abstract][Full Text] [Related]
25. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
Crumb WJ; Vicente J; Johannesen L; Strauss DG
J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
[TBL] [Abstract][Full Text] [Related]
26. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.
Rampe D; Murawsky MK; Grau J; Lewis EW
J Pharmacol Exp Ther; 1998 Aug; 286(2):788-93. PubMed ID: 9694935
[TBL] [Abstract][Full Text] [Related]
27. Utility of frozen cell lines in medium throughput electrophysiology screening of hERG and NaV1.5 blockade.
Donovan BT; Bakshi T; Galbraith SE; Nixon CJ; Payne LA; Martens SF
J Pharmacol Toxicol Methods; 2011; 64(3):269-76. PubMed ID: 21996251
[TBL] [Abstract][Full Text] [Related]
28. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
29. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action.
Busch AE; Eigenberger B; Jurkiewicz NK; Salata JJ; Pica A; Suessbrich H; Lang F
Br J Pharmacol; 1998 Jan; 123(1):23-30. PubMed ID: 9484850
[TBL] [Abstract][Full Text] [Related]
30. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
Wible BA; Hawryluk P; Ficker E; Kuryshev YA; Kirsch G; Brown AM
J Pharmacol Toxicol Methods; 2005; 52(1):136-45. PubMed ID: 15950494
[TBL] [Abstract][Full Text] [Related]
31. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
Bridgland-Taylor MH; Hargreaves AC; Easter A; Orme A; Henthorn DC; Ding M; Davis AM; Small BG; Heapy CG; Abi-Gerges N; Persson F; Jacobson I; Sullivan M; Albertson N; Hammond TG; Sullivan E; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2006; 54(2):189-99. PubMed ID: 16563806
[TBL] [Abstract][Full Text] [Related]
32. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG.
Kang J; Chen XL; Wang L; Rampe D
J Pharmacol Exp Ther; 2001 Oct; 299(1):290-6. PubMed ID: 11561091
[TBL] [Abstract][Full Text] [Related]
33. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents.
Danielsson BR; Lansdell K; Patmore L; Tomson T
Epilepsy Res; 2005 Jan; 63(1):17-25. PubMed ID: 15716081
[TBL] [Abstract][Full Text] [Related]
34. Flunarizine is a highly potent inhibitor of cardiac hERG potassium current.
Trepakova ES; Dech SJ; Salata JJ
J Cardiovasc Pharmacol; 2006 Feb; 47(2):211-20. PubMed ID: 16495758
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel.
Potet F; Bouyssou T; Escande D; Baró I
J Pharmacol Exp Ther; 2001 Dec; 299(3):1007-12. PubMed ID: 11714889
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
[TBL] [Abstract][Full Text] [Related]
37. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds.
Tao H; Santa Ana D; Guia A; Huang M; Ligutti J; Walker G; Sithiphong K; Chan F; Guoliang T; Zozulya Z; Saya S; Phimmachack R; Sie C; Yuan J; Wu L; Xu J; Ghetti A
Assay Drug Dev Technol; 2004 Oct; 2(5):497-506. PubMed ID: 15671647
[TBL] [Abstract][Full Text] [Related]
38. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
[TBL] [Abstract][Full Text] [Related]
39. Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.
Bridal TR; Margulis M; Wang X; Donio M; Sorota S
Assay Drug Dev Technol; 2010 Dec; 8(6):755-65. PubMed ID: 20658944
[TBL] [Abstract][Full Text] [Related]
40. Block of HERG current expressed in HEK293 cells by the Na+-channel blocker cibenzoline.
Hiramatsu M; Wu LM; Hirano Y; Kawano S; Furukawa T; Hiraoka M
Heart Vessels; 2004 May; 19(3):137-43. PubMed ID: 15168062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]